Weight-loss drugs from Lilly, Novo linked to stalling cancer: report
Seeking Alpha • • health
Key Points:
- New research indicates that GLP-1 drugs, commonly used for weight loss and diabetes, may improve outcomes for cancer patients.
- Four recent studies highlight the potential cancer-related benefits of medications like those produced by Novo Nordisk.
- These findings suggest an additional therapeutic advantage for GLP-1 drugs beyond their established uses.
- The research could influence future treatment approaches for cancer patients using these medications.